Becton, Dickinson and Company

Key catalysts

• Recurring clinical supplies

  A broad installed base supports repeat demand for needles, syringes, diagnostic consumables and medication-management supplies.

• Innovation pipeline

  New pharmacy automation, microbiology and interventional products can improve mix and customer workflows.

• Portfolio separation

  A focused separation can simplify the remaining business and sharpen capital allocation if executed cleanly.

Principal risks

• Separation complexity

  Carve-out costs, stranded overhead and operational disruption could dilute expected portfolio benefits.

• Quality and regulatory risk

  Medical-device recalls, remediation or regulatory findings can interrupt supply and raise costs.

• Hospital budget pressure

  Provider labor and capital constraints can delay equipment upgrades and pressure pricing.

BD's fiscal second-quarter 2026 update reflected demand across medication delivery, diagnostics and interventional products while the company continued portfolio-separation work and productivity initiatives.

Valuation interpretation

• Recurring consumables support defensiveness, but the quality discount narrows only with consistent execution and product reliability.
• Separation value should be assessed net of stranded costs, transition spending and the loss of diversification.